Longevity Market By Offering, By Application, By End User, By Distribution Channel and Regional Insights 2034
Overview
The Global Longevity Market was valued at USD 31.6 billion in 2025 and is expected to reach USD 98.8 billion by 2034, growing at a CAGR of 13.5% during 2026–2034.
The market covers the products, tests and services built to extend health span, meaning the years a person lives in good health. That includes biological age testing, geroscience therapeutics, NAD+ and other longevity supplements, preventive clinics with full-body scanning, and wearables that track ageing biomarkers.
The World Health Organization (WHO) reports that the number of people aged 60 and above will rise from 1.0 billion in 2020 to 1.4 billion in 2030 and 2.1 billion in 2050. Chronic disease turns that demographic shift into spending: the US Centers for Disease Control and Prevention (CDC) states that 90% of the nation’s USD 4.5 trillion in annual health expenditure goes to people with chronic and mental health conditions. Prevention, early detection and healthspan science are now being funded as a response to both facts.
Diagnostics and testing lead the shift toward measurable ageing, supplements remain the largest offering by revenue in 2025, and geroscience therapeutics are the fastest-growing offering. North America holds the largest regional share, while Asia Pacific is the fastest-growing region. In 2026, the category moved from promise toward evidence, with a first human trial of partial epigenetic reprogramming, a USD 144 million US government healthspan programme and a public regulatory forum on how ageing-related products could be assessed.
| 2025 | Base Year USD 31.6 Bn |
2034 | Forecast USD98.8 Bn |
Growth Rate (CAGR) 13.5% |
Largest Region North America |
|---|
Longevity Market Overview
Longevity refers to the length of an individual's life, with an emphasis on extending healthy lifespan through preventive healthcare, medical innovation, nutrition, and lifestyle interventions. It focuses on delaying age-related diseases, improving physical and cognitive functions, and enhancing overall quality of life through scientific advancements in ageing research and personalized medicine.
Global Longevity Market at the level of consumer and provider spending on products and services whose stated purpose is to extend healthspan, measure biological ageing or delay age-related decline. The scope spans five offerings: diagnostics and biological age testing, geroscience therapeutics, nutraceuticals and supplements, clinics and preventive services, and wearables and digital healthspan tools. Veterinary longevity, led by Loyal’s canine programme, is tracked as a leading indicator of regulatory direction rather than counted in the base.
The measurement is becoming the entry point: consumers buy a test, scan or subscription before they buy an intervention. The therapeutics are moving into human trials, which brings regulators into the conversation, driving Longevity Market Growth. Public money has arrived, with the US Advanced Research Projects Agency for Health (ARPA-H) funding human trials that use intrinsic capacity, a composite of cognition, mobility, psychological function, vitality and sensory ability, as the primary endpoint.
Why Choose the MMR Global Longevity Market Report?
Longevity is a category where claims travel faster than evidence, and published estimates vary widely because analysts draw the boundary in different places. The MMR Longevity Market report is written to remove that ambiguity. It defines the Global Longevity Market explicitly, builds the forecast bottom-up from five offerings and five regions, and anchors the demand case in government and regulator data rather than in marketing statements.
Longevity Market Growth and Share Analysis

To know about the Research Methodology :- Request Free Sample Report
Global Longevity Market Key Insights
| No. | Strategic Finding | Supporting Evidence | Strategic Implications |
| 01 | Market Growth creates significant growth opportunities | Market value increases from USD 31.6 Bn in 2025 to USD 98.8 Bn by 2034, at a 13.5% CAGR. | Companies should prioritize capacity expansion, clinical pipeline development and distribution partnerships. |
| 02 | Therapeutics emerge as the fastest-growing segment | Supplements account for XX% of 2025 revenue, while geroscience therapeutics record the highest projected CAGR of XX%. | Competitive advantage is expected to shift toward clinically validated longevity interventions and differentiated therapeutic portfolios. |
| 03 | North America maintains market leadership | North America represents 38.0% of global revenue in 2025, equivalent to USD 12.0 Bn. | Regulatory developments, venture investment and commercialization strategies in the US will remain important market indicators. |
| 04 | Asia Pacific presents the strongest regional growth potential | Asia Pacific accounts for XX% of 2025 market revenue, with a projected CAGR of XX%. | Companies should evaluate expansion opportunities in Japan, South Korea and China through localized products and strategic partnerships. |
| 05 | Population ageing establishes a structural demand foundation | WHO projects the global population Aged 60+ to increase from 1.0 Bn in 2020 to 1.4 Bn in 2030 and 2.1 Bn in 2050. | Long-term demographic changes support investment in preventive healthcare, biological age diagnostics and healthy-ageing solutions. |
| 06 | Government investment accelerates clinical innovation | ARPA-H announced up to USD 144 Mn for seven PROSPR research teams on 24 February 2026. | Public funding creates opportunities for biomarker validation, clinical research partnerships and development of healthspan assessment frameworks. |
| 07 | Regulatory validation remains critical for commercialization | The Reagan-Udall Foundation forum on 27 May 2026 highlighted the absence of an FDA-approved indication for ageing itself and accepted ageing-related endpoints. | Developers should prioritize disease-specific indications, clinical evidence generation and regulatory engagement. |
Global Longevity Market Trends
Increasing Adoption of Biological Age Testing, AI-Driven Diagnostics and Personalized Healthcare
The Global Longevity Market is experiencing significant technological transformation, driven by advancements in biological age testing, artificial intelligence, regenerative medicine and personalized preventive healthcare. A major Longevity Market Trend is the expansion of preventive health screening and subscription-based longevity services. In January 2026, Neko Health announced that more than 300,000 individuals had registered their interest in its preventive health screening services globally. The company subsequently announced USD 700 million in Series C financing in July 2026, highlighting investor interest in technology-enabled preventive healthcare.
The development of geroscience therapeutics is also gaining momentum. In January 2026, Life Biosciences announced FDA clearance of its investigational new drug application for ER-100, advancing partial epigenetic reprogramming into human clinical evaluation. Function Health announced USD 450 million in growth financing in July 2026, supporting the expansion of personalized diagnostics and preventive healthcare services.
Global Longevity Market Drivers
Expanding Ageing Population, Chronic Disease Burden and Government Research Funding
The increasing global ageing population is a primary driver of demand for longevity therapeutics, preventive healthcare services and healthy-ageing products. According to the World Health Organisation, the population aged 60 years and above is expected to increase from 1.0 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. The population aged 80 years and above is also expected to reach 426 million by 2050, strengthening long-term demand for age-related healthcare solutions.
The annual healthcare expenditure was associated with people living with chronic and mental health conditions, based on the earlier CDC expenditure series. The XPRIZE Healthspan competition carries a USD 101 million prize purse, encouraging research into interventions targeting age-related functional decline.
Global Longevity Market Restraints: Regulation, Evidence Gaps and Competitive Pressure
Lack of Regulatory Approval for Ageing Treatments
The absence of an FDA-approved indication for ageing itself remains a significant barrier to the commercialization of longevity therapeutics.
The Reagan-Udall Foundation meeting held on 27 May 2026 highlighted the lack of validated ageing biomarkers and accepted clinical endpoints for gerotherapeutic claims.
Extended Clinical Trial Timelines and High Development Costs
Longevity therapeutics require extensive clinical evaluation to establish safety, efficacy and long-term treatment outcomes.
Life Biosciences' ER-100 Phase 1 programme targets glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with initial emphasis on safety assessment.
Increasing Competition and Pricing Pressure in Longevity Supplements
Growing competition among nutraceutical manufacturers, NAD+ supplement providers and healthy-ageing brands is intensifying pricing and product differentiation challenges.
Niagen Bioscience reported net sales of USD 27.2 million in Q3 2026, compared with USD 34.0 million in Q3 2025, representing a 20.0% year-on-year decline.
Regulatory Compliance and Unsubstantiated Longevity Claims
The lack of universally accepted clinical endpoints for ageing-related interventions creates regulatory uncertainty for longevity products and services.
Companies promoting age-reversal, lifespan extension and biological rejuvenation claims face compliance risks when supporting clinical evidence is insufficient.
Concentration of Investment Capital Among Established Longevity Companies
Venture capital investment in advanced longevity technologies is concentrated among a limited number of well-funded biotechnology and cellular reprogramming companies.
Smaller developers face challenges securing sufficient funding for early-stage research, clinical trials and commercialization.
Global Longevity Market Opportunities Through 2034
| Opportunity | Basis | Description |
| Biomarker and clock validation | PROSPR is building a PROSPR intrinsic capacity score; Stanford’s team received up to USD 34 Mn | Diagnostics providers whose tests become accepted endpoints |
| Disease-first gerotherapeutics | FDA clearance of the ER-100 IND (28 January 2026) shows a disease-indication route exists | Developers with a defined organ or disease entry point |
| Subscription preventive health | Function Health integrated lab testing, imaging (Ezra) and at-home draws (Getlabs) | Platforms that combine data, imaging and follow-on services |
| Clinic networks and scanning | Neko Health opened its first US clinic on 24 September 2026 | Operators able to repeat a standard protocol across cities |
| Asia Pacific demand | UN data show South Korea’s 65+ share rising from 19.3% (2024) to 39.7% (2050) and Japan’s at 29.8% (2024) | Regional partnerships in testing, supplements and clinics |
Global Longevity Market Segment Analysis
Based on Application, Cardiometabolic Health is a leading application area in the Global Longevity Market in 2025, supported by increasing demand for cardiovascular disease prevention, metabolic health optimization, and personalized longevity healthcare. Rising prevalence of diabetes, obesity, hypertension, and age-related cardiovascular disorders is encouraging the adoption of advanced biomarker testing, continuous glucose monitoring, and preventive cardiology services.
According to the US Centers for Disease Control and Prevention (CDC), February 2026, 40.3% of American adults aged 20 years and above had obesity during August 2021–August 2023, including 9.7% with severe obesity. Obesity prevalence reached 46.4% among adults aged 40–59, highlighting substantial cardiometabolic health risks. The support demand for preventive cardiology, metabolic health screening, continuous glucose monitoring, personalized nutrition, and early intervention programmes. Healthcare providers are increasingly exploring AI-powered diagnostics, wearable health technologies, and individualised treatment strategies to address metabolic dysfunction and improve long-term health outcomes, driving Longevity Market growth.
Global Longevity Market by Offering: Diagnostics, Therapeutics, Supplements, Clinics and Wearables
Nutraceuticals & Supplements accounted for the largest Longevity Market 2025 share. The segment's leadership is supported by increasing consumer demand for healthy ageing supplements, preventive nutrition, and personalized wellness solutions. Growing adoption of NAD+ precursors, antioxidants, omega-3 fatty acids, collagen supplements, and cellular health formulations is expanding product demand.
According to the US Centers for Disease Control and Prevention (CDC), 75.9% of adults aged 60 years and above used dietary supplements during August 2021–August 2023, compared with 60.3% of adults aged 40–59. Additionally, 56.4% of adults aged 60 and above consumed two or more supplements, indicating substantial nutritional supplement adoption among older consumers.
Global Longevity Market Size, Share and Growth Forecast by Offering (2025–2034)
| Offering | 2025 share | 2025 value (USD Bn) | 2034 value (USD Bn) | CAGR 2025–2034 |
| Nutraceuticals & Supplements | 31.0% | XX | XX | XX% |
| Diagnostics & Biological Age Testing | XX% | XX | XX | XX% |
| Clinics & Preventive Services | XX% | XX | XX | XX% |
| Geroscience Therapeutics | XX% | XX | XX | XX% |
| Wearables & Digital Health span Tools | XX% | XX | XX | XX% |
Companies such as Niagen Bioscience, Elysium Health, and L-Nutra are expanding longevity-focused product portfolios through nutritional innovation and direct-to-consumer distribution. Increasing e-commerce accessibility and personalized nutrition programmes support segment development.
Nutraceuticals & Supplements dominated the Global Longevity Market, supported by increasing demand for healthy ageing products, preventive nutrition, and personalized wellness solutions. Diagnostics & Biological Age Testing followed, driven by growing adoption of biomarker screening and precision medicine. Clinics & Preventive Services benefited from expanding longevity clinics and preventive healthcare programmes. Geroscience Therapeutics gained momentum through advancements in biotechnology, cellular rejuvenation, and clinical research. Meanwhile, Wearables & Digital Healthspan Tools experienced increasing adoption, supported by AI-powered diagnostics, continuous health monitoring, and growing consumer awareness of healthspan optimization and personalized preventive healthcare.

Nutraceuticals & Supplements dominated the market in 2025, accounting for 31.0% of total revenue. However, Diagnostics & Biological Age Testing are expected to emerge as the largest offering by 2034, supported by advancements in biomarker analysis and personalized medicine. Geroscience Therapeutics are projected to experience the fastest growth, while longevity clinics and digital healthspan tools will benefit from increasing adoption of AI-powered diagnostics and continuous health monitoring.
Global Longevity Market Regional Insights
North America dominated the Longevity Market in 2025 with the largest market share. The region's leadership is supported by advanced healthcare infrastructure, increasing adoption of preventive healthcare, and substantial investment in longevity biotechnology. According to the US Census Bureau, 18.0% of the US population was aged 65 years and above in 2024, strengthening demand for healthy ageing solutions, personalized medicine, and age-related disease prevention.
Altos Labs launched in 2022 with USD 3 billion in committed capital, highlighting significant private investment in cellular rejuvenation and regenerative medicine. The growing presence of biotechnology companies, longevity clinics, and digital health platforms is accelerating innovation in biological age testing and AI-powered diagnostics. Rising consumer awareness, clinical research activities, and increasing demand for healthspan optimization are expected to support North America's Longevity Market leadership through 2034.In 2026, Life Biosciences secured USD 80 million in Series D financing to advance its longevity therapeutics pipeline. Additionally, Function Health announced USD 450 million in growth financing, highlighting investment in personalized diagnostics and preventive healthcare. These developments strengthen the region's position in geroscience research, biological age testing, and healthspan innovation.
Global Longevity Market Funding Signal: Where Capital Moved in 2026
The Global Longevity Market is attracting significant venture capital investment in longevity biotechnology, preventive healthcare, biological age testing, and cellular reprogramming technologies. In 2026, Neko Health secured USD 700 million in Series C funding, followed by Function Health's USD 450 million growth financing and NewLimit's USD 435 million Series C investment. The investments support geroscience research, AI-driven diagnostics, regenerative medicine, healthspan innovation, and clinical commercialization opportunities worldwide.
Global Longevity Market Competitive Landscape
The Global Longevity Market is characterized by a fragmented competitive landscape, with biotechnology companies, longevity startups, preventive healthcare providers, and nutraceutical manufacturers competing across different product categories. Leading geroscience companies, including Altos Labs, Retro Biosciences, and Life Biosciences, focus on cellular rejuvenation, epigenetic reprogramming, and age-related disease therapeutics. Meanwhile, Function Health and Neko Health are expanding personalized preventive healthcare through advanced biomarker testing, AI-powered diagnostics, and subscription-based health screening services.
Nutraceutical manufacturers compete through NAD+ supplements, healthy ageing formulations, product innovation, and digital distribution channels. Strategic partnerships, venture capital funding, clinical trials, and regulatory approvals are shaping competitive positioning. Market participants are increasingly investing in precision medicine, regenerative therapies, biological age assessment, and healthspan optimization technologies. MMR evaluates the longevity industry competitive landscape through company benchmarking, technology portfolios, funding activities, clinical development pipelines, geographic expansion, and commercialization strategies to identify emerging investment opportunities and competitive advantages.
Key Players in the Global Longevity Market:
| Company | Offering | Headquarters | Description |
| Altos Labs | Therapeutics | Redwood City, USA | Launched in 2022 with USD 3 Bn of committed capital; focused on cellular rejuvenation |
| Retro Biosciences | Therapeutics | San Francisco, USA | Priced round at a USD 1.8 Bn pre-money valuation led by 4P Capital (May 2026); RTR242 in first-in-human dosing |
| NewLimit | Therapeutics | USA | USD 435 Mn Series C at a USD 3.1 Bn valuation led by Founders Fund (2 June 2026); first human trial planned for 2027 |
| Life Biosciences | Therapeutics | Boston, USA | FDA IND clearance for ER-100, the first partial epigenetic reprogramming therapy in human trials (28 January 2026); USD 80 Mn Series D |
| Linnaeus Therapeutics | Therapeutics | Haddonfield, USA | ARPA-H PROSPR contract of up to USD 22 Mn for LNS8801 (24 February 2026) |
| Longeveron | Cell therapy | Miami, USA | XPRIZE Healthspan Milestone 2 awardee with a USD 1 Mn award (11 August 2026) |
| Loyal | Veterinary longevity | San Francisco, USA | FDA CVM accepted the LOY-002 safety section (13 January 2026); USD 100 Mn Series C led by age1 (11 February 2026) |
| Function Health | Diagnostics | Austin, USA | Acquired Getlabs (8 April 2026); USD 450 Mn growth financing from General Catalyst’s Customer Value Fund (29 July 2026) |
Other participants profiled in the report include Calico Life Sciences, Juvenescence, BioAge Labs, Insilico Medicine, Human Longevity Inc., Fountain Life, Prenuvo, Oura, WHOOP, Tally Health, Elysium Health, Timeline, Turn Biotechnologies, Rejuvenate Bio and Shift Bioscience. Public institutions and standard-setters covered include WHO, ARPA-H, the US National Institute on Aging, the US FDA and the Reagan-Udall Foundation for the FDA.
Global Longevity Market Recent Developments:
| Date | Company / body | Development |
| 13 January 2026 | Loyal | FDA Center for Veterinary Medicine accepted the Target Animal Safety section for LOY-002, the first known safety acceptance for a lifespan-extension drug |
| 14 January 2026 | Neko Health | Announced its first US location in New York City; more than 300,000 people had signed up globally |
| 28 January 2026 | Life Biosciences | FDA cleared the IND for ER-100, the first partial epigenetic reprogramming therapy to enter human trials |
| 11 February 2026 | Loyal | Raised USD 100 Mn Series C led by age1 to complete remaining FDA requirements and prepare for launch |
| 24 February 2026 | ARPA-H | Announced PROSPR awards totalling up to USD 144 Mn across seven teams, including up to USD 38 Mn for UT Health San Antonio’s VITAL-H trial |
| 8 April 2026 | Function Health | Acquired Getlabs to offer at-home and in-office blood draws |
| 16 April 2026 | Nula Therapeutics | Launched with an ARPA-H PROSPR award of up to USD 20 Mn for NLT-101 |
| 22 May 2026 | Retro Biosciences | Announced a priced round at a USD 1.8 Bn pre-money valuation led by 4P Capital |
| 27 May 2026 | Reagan-Udall Foundation for the FDA | Convened a public meeting with ARPA-H and XPRIZE on regulatory constructs for gerotherapeutics |
| 2 June 2026 | NewLimit | Raised USD 435 Mn Series C at a USD 3.1 Bn valuation to fund its first human trial |
| 15 July 2026 | Neko Health | Raised USD 700 Mn Series C led by Lightspeed Venture Partners |
| 29 July 2026 | Function Health | Secured USD 450 Mn growth financing from General Catalyst’s Customer Value Fund |
Global Longevity Market Scope:Inquire before buying
| Global Longevity Market | |||
|---|---|---|---|
| Report Coverage |
Details | ||
| Base Year: | 2025 | Forecast Period: |
2026–2034 |
| Historical Data: |
2020 to 2025 |
Market Size in 2025: |
USD 31.6 Billion |
| Forecast Period 2026 to 2034 CAGR: | 13.50% | Market Size in 2034: |
USD 98.8 Billion |
| Global Longevity Market Segment Analysis | By Offering | Diagnostics & Biological Age Testing Geroscience Therapeutics Nutraceuticals & Supplements Clinics & Preventive Services Wearables & Digital Healthspan Tools Others |
|
| By Application | Cardiometabolic Health; Cognitive & Neurological Health; Musculoskeletal Health & Mobility Skin & Aesthetic Ageing; Immune Function & General Healthspan Others |
||
| By End User | Individual Consumers; Clinics & Healthcare Providers; Corporate Wellness Programmes & Payers; Research Institutes & Biotechnology Companies Others |
||
| By Distribution Channel | Direct-to-Consumer & Online; Clinics & Hospitals; Specialty & Retail Pharmacies; Telehealth Platforms Others |
||
Longevity Market Market, By Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Key players/Competitors profiles covered in the Longevity Market report from a strategic perspective
North America
1. Altos Labs, Inc. (United States)
2. Calico Life Sciences LLC (United States)
3. Retro Biosciences, Inc. (United States)
4. NewLimit, Inc. (United States)
5. Life Biosciences, Inc. (United States)
6. BioAge Labs, Inc. (United States)
7. Cambrian Bio (United States)
8. Rubedo Life Sciences, Inc. (United States)
9. Longeveron Inc. (United States)
10. Rejuvenate Bio, Inc. (United States)
11. Turn Biotechnologies, Inc. (United States)
12. Human Longevity, Inc. (United States)
13. Function Health (United States)
14. Fountain Life (United States)
15. Prenuvo (United States)
16. Elysium Health, Inc. (United States)
17. Niagen Bioscience, Inc. (United States)
18. Oura Health (United States)
19. WHOOP, Inc. (United States)
20. Tally Health, Inc. (United States)
21. L-Nutra, Inc. (United States)
22. Oisín Biotechnologies, Inc. (United States)
23. Juvena Therapeutics, Inc. (United States)
24. Casma Therapeutics, Inc. (United States)
25. BlueRock Therapeutics (Canada)
Europe
26. Neko Health AB (Sweden)
27. Juvenescence Limited (United Kingdom)
28. Shift Bioscience Ltd. (United Kingdom)
29. clock.bio Ltd. (United Kingdom)
30. Genflow Biosciences plc (United Kingdom)
31. Rejuveron Life Sciences AG (Switzerland)
32. Maximon AG (Switzerland)
33. Timeline (Switzerland)
34. GlycanAge Ltd. (United Kingdom)
35. GlycanAge's parent company Genos Ltd. (Croatia)
36. TreeFrog Therapeutics (France)
37. Cellvie GmbH (Germany)
38. VitaDAO (Switzerland)
39. Rewind Therapeutics (Belgium)
40. NOVOS Labs (United States)
Asia Pacific
41. Gero Pte. Ltd. (Singapore)
42. Deep Longevity Limited (Hong Kong)
43. Insilico Medicine (Hong Kong)
44. BGI Genomics Co., Ltd. (China)
45. Eisai Co., Ltd. (Japan)
46. Shiseido Company, Limited (Japan)
47. Mesoblast Limited (Australia)
Middle East & Africa
48. Insilico Medicine (United Arab Emirates)
49. PureHealth Holding PJSC (United Arab Emirates)
South America
50. Grupo Fleury S.A. (Brazil)
Others
